Datar Cancer Genetics ("Datar"), a leading cancer research company focused on early detection of cancers, is pleased to announce that it has partnered with Acecgt to offer its cancer solutions in Hong Kong and Macao. Particularly, Trucheck is an innovative cancer screening test that requires a safe, simple and quick blood draw, allowing for early detection of cancer by detecting Circulating Tumor Cells.
“We are thrilled about the opportunity to Datar Cancer Genetics," said Dr. Billy Chan, CEO of Acecgt Group. "We can leverage their extensive experience and ground-breaking technologies from early cancer screening to cancer management while catering specifically to the needs of our local community. The combined strengths of both organizations will ensure that residents of Hong Kong and Macao have access to world-class stage of the art cancer tests with very high accuracy. Patients can expect reliable results delivered promptly by highly skilled professionals”.
Dr Vineet Datta, Executive Director at Datar, said: “We are delighted to partner with Acecgt, which will provide our advanced cancer detection solutions to the individuals and clinical community across Hong Kong and Macao. Trucheck is a CE certified cancer screening solution offered for single and multi-organ cancer screening. Our cancer screening portfolio offers a new paradigm in multi-cancer detection and is aimed to complement the current standardized clinical pathways that aid early cancer detection".
Datar is a leading cancer research corporation specializing in non-invasive techniques for better screening, diagnosis, and management of cancer. Datar has a College of American Pathologists (CAP) and CLIA accredited molecular genomic facility in the United Kingdom, in addition to globally accredited lab facilities in India and the United States. Our team of scientists, clinicians, advisors and experts, based out of the United Kingdom, U.S.A., Germany and India, help advance our innovative technologies for better cancer management.
Acecgt is a Hong Kong based leading clinical diagnostic laboratory committed in bringing innovative, affordable and widely accessible testing solutions into everyday clinical practice within multiple specialties throughout their network. Leveraging the vast amount of knowledge and know-how derived from the Human Genome Project, International HapMap and other oncology research programs, Acecgt is translating the science of molecular diagnostics and personalized medicine into clinical practice within the Hong Kong and Macao Special Administrative Regions of China. For more information, visit www.acecgtdiagnostic.com